Trial Profile
Phase I, Open-label Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of SPH1188-11 Tablets for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 12 Nov 2021
Price :
$35
*
At a glance
- Drugs SPH 1188-11 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Shanghai Pharmaceuticals Holding
- 31 Oct 2021 Planned End Date changed from 1 Mar 2020 to 31 Mar 2022.
- 31 Oct 2021 Status changed from recruiting to withdrawn prior to enrolment.
- 16 Aug 2017 Status changed from not yet recruiting to recruiting.